Dr. Sarah C. Rutherford, MD

Dr. Rutherford practices at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital.

Dr. Rutherford's NPI, 1245467752, was assigned on June 11, 2009. Dr. Rutherford graduated from University of Virginia School of Medicine in 2009. Dr. Rutherford holds New York license 263401.

Dr. Rutherford's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center, at 525 East 68th Street, New York, NY 10065 in New York County. The practice phone is (212) 746-5454.

Dr. Rutherford's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital. Dr. Rutherford is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Rutherford to 2 more clinical labs, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rutherford practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Rutherford's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Rutherford is licensed in New York.

CMS data shows 801 Medicare services from Dr. Rutherford across 7 procedure codes in 2024, for 227 Medicare patients. Medicare paid $87,280 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 227 Medicare patients who saw Dr. Rutherford in 2024. The largest group is 75 to 84, with 88 patients. 75% of them have high cholesterol, and 68% have high blood pressure. 18% are also on Medicaid. Their average risk score is 2.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rutherford's median patient age at 74, with 56% women.

In 2024, Dr. Rutherford wrote 73 Medicare Part D claims for 31 patients. 90% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $25 in total drug cost. In 2023, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Rutherford for performance year 2024, reported through an alternative payment model (APM). Dr. Rutherford accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rutherford as offering telehealth.

Dmand AI links 30 papers to Dr. Rutherford, published from 2015 to 2025. 2021 was the busiest year, with 4. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse and Doxorubicin. Dr. Rutherford has published most often in Blood. Dr. Rutherford's most frequent co-authors are John P. Leonard, MD, Peter Martin, MD and Nancy Lee Bartlett, MD.

Dmand AI links Dr. Rutherford to 6 clinical trials. 3 are still active or recruiting. Conditions studied include Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse and Hodgkin Disease. National Cancer Institute (NCI) sponsors the most, 2. Open Payments lists research payments to Dr. Rutherford that name 2 trials.

CMS Open Payments shows 131 general payments to Dr. Rutherford from 19 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 79% of the total. Seagen Inc. paid the most, $21,814. It also lists 7 research payments totaling $234,967 from 2016 to 2020, naming 2 clinical trials.

Dr. Rutherford graduated from University of Virginia School of Medicine in 2009.